Concentration:	1 mg / ml, determined by the Lowry method
Source:	From fresh human plasma that has tested negative for Hepatitis C, HIV-I and HIV-II antibodies as well as Hepatitis surface antigens.
Purification:	After series ultracentrifugations, Very Low Density Lipoprotein (VLDL) is isolated from human plasma. Apo CIII is purified from delepidated VLDL, followed by gel-filtration and DEAE-Sepharcyl chromatography. Minor impurities of other apo-proteins are then removed by antibody-Sepharose™ affinity column.
Purity:	≥ 99% by SDS-PAGE
Buffer:	In 10 mM Tris-HCl, 0.15 M NaC1, 0.5 mM EDTA, 0.02 % NaN3, pH 8.0
Storage:	-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

*The products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

 

Importance

Apo CIII contains 79 amino acid residues. The m.w. is 8.7 kDa (Brewer et al., 1974).

It may inhibit the activation of lipoprotein lipase by apo CIII. Apo CIII is a constituent of both apoB- and apoAI-containing lipoproteins in the circulation. Apo CIII plays a pivotal role in regulating the plasma metabolism of VLDL, IDL, and LDL, primarily by inhibiting receptor-mediated uptake of these lipoproteins by the liver (Sehayek and Eisenberg 1991, Aalto-Setala et al., 1992, Zheng et al., 2007)

Brewer, H. B., R. Shulman, P. Herbert, R. Ronan, and K. Wehrly. “The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins.” J Biol Chem 249.15 (1974):4975-84.

Sehayek , E. , and S. Eisenberg . “Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.” J. Biol. Chem. 266 (1991) : 18259 – 18267 .

Aalto-Setala , K., E. A. Fisher , X. Chen , T. Chajek-Shaul , T. Hayek , R. Zechner , A. Walsh , R. Ramakrishnan , H. N. Ginsberg , and J. L. Breslow . “ Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.” J. Clin. Invest. 90 (1992): 1889 – 1900.

Zheng , C. , C. Khoo , K. Ikewaki , and F. M. Sacks . “ Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.” J. Lipid Res. 48 (2007): 1190 -203.

 

Citations

[P14][P15]	2017	Toth, Christopher A.; Kuklenyik, Zsuzsanna; Jones, Jeffrey I.; Parks, Bryan A.; Gardner, Michael S.; Schieltz, David M. et al. (2017): On-column trypsin digestion coupled with LC-MS/MS for quantification of apolipoproteins. In Journal of proteomics 150, pp. 258–267. DOI: 10.1016/j.jprot.2016.09.011.
[P14][P15]	2016	Koska, Juraj; Yassine, Hussein; Trenchevska, Olgica; Sinari, Shripad; Schwenke, Dawn C.; Yen, Frances T. et al. (2016): Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. In Journal of lipid research 57 (5), pp. 894–905. DOI: 10.1194/jlr.P064816.
[P14][P15]	2013	Zheng, Chunyu; Azcutia, Veronica; Aikawa, Elena; Figueiredo, Jose-Luiz; Croce, Kevin; Sonoki, Hiroyuki et al. (2013): Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. In European Heart Journal 34 (8), pp. 615–624. DOI: 10.1093/eurheartj/ehs271.
[P14][P15]	2011	Holleboom, Adriaan G.; Karlsson, Helen; Lin, Ruei-Shiuan; Beres, Thomas M.; Sierts, Jeroen A.; Herman, Daniel S. et al. (2011): Heterozygosity for a Loss-of-Function Mutation in GALNT2 Improves Plasma Triglyceride Clearance in Man. In Cell metabolism 14 (6), pp. 811–818. DOI: 10.1016/j.cmet.2011.11.005.
[P14][P15]	2010	Abe, Yasuko; Kawakami, Akio; Osaka, Mizuko; Uematsu, Satoshi; Akira, Shizuo; Shimokado, Kentaro et al. (2010): Apolipoprotein CIII induces monocyte chemoattractant protein-1 and interleukin 6 expression via Toll-like receptor 2 pathway in mouse adipocytes. In Arterioscler Thromb Vasc Biol. 30 (11), pp. 2242–2248. DOI: 10.1161/ATVBAHA.110.210427.
[P14][P15]	2010	Mazur, Matthew T.; Cardasis, Helene L.; Spellman, Daniel S.; Liaw, Andy; Yates, Nathan A.; Hendrickson, Ronald C. (2010): Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry. In Proc Natl Acad Sci USA 107 (17), pp. 7728–7733. DOI: 10.1073/pnas.0910776107.
[P14][P15]	2007	Kawakami, Akio; Aikawa, Masanori; Nitta, Noriko; Yoshida, Masayuki; Libby, Peter; Sacks, Frank M. (2007): Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. In Arterioscler Thromb Vasc Biol. 27 (1), pp. 219–225. DOI: 10.1161/01.ATV.0000249620.68705.0d.
[P14][P15]	2007	Kawakami, Akio; Aikawa, Masanori; Nitta, Noriko; Yoshida, Masayuki; Libby, Peter; Sacks, Frank M. (2007): Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. In Arterioscler Thromb Vasc Biol. 27 (1), pp. 219–225. DOI: 10.1161/01.ATV.0000249620.68705.0d.
[P14][P15]	2006	Kawakami, Akio; Aikawa, Masanori; Alcaide, Pilar; Luscinskas, Francis W.; Libby, Peter; Sacks, Frank M. (2006): Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. In Circulation 114 (7), pp. 681–687. DOI: 10.1161/CIRCULATIONAHA.106.622514.
[P14][P15]	2006	Kawakami, Akio; Aikawa, Masanori; Libby, Peter; Alcaide, Pilar; Luscinskas, Francis W.; Sacks, Frank M. (2006): Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. In Circulation 113 (5), pp. 691–700. DOI: 10.1161/CIRCULATIONAHA.105.591743.
[P14][P15]	2006	Schaap, Frank G.; Nierman, Melchior C.; Berbée, Jimmy F. P.; Hattori, Hiroaki; Talmud, Philippa J.; Vaessen, Stefan F. C. et al. (2006): Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. In J. Lipid Res. 47 (10), pp. 2333–2339. DOI: 10.1194/jlr.M500533-JLR200.
[P14][P15]	2005	Gerritsen, Gery; Rensen, Patrick C. N.; Kypreos, Kyriakos E.; Zannis, Vassilis I.; Havekes, Louis M.; van Willems Dijk, Ko (2005): ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression. In J. Lipid Res. 46 (7), pp. 1466–1473. DOI: 10.1194/jlr.M400479-JLR200.
[P14][P15]	2002	Olin-Lewis, Katherine; Krauss, Ronald M.; La Belle, Michael; Blanche, Patricia J.; Barrett, P. Hugh R.; Wight, Thomas N.; Chait, Alan (2002): ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. In J. Lipid Res. 43 (11), pp. 1969–1977. DOI: 10.1194/jlr.M200322-JLR200.

academy biomed[A05]绵羊抗人类载脂蛋白AII多克隆抗体12A-S1a学院生物医学公司$ 155.00$ 155.00目录号数量1寄主物种： 羊浓度： 1毫克/毫升（OD 1.35 / 280 nm）抗原： 人类载脂蛋白AII纯化： 亲和纯化缓冲： 75 mM磷酸钠，75 mM NaCl，0.5 mM EDTA，0.02％NaN3，pH 7.2特异性 与人载脂蛋白AII特异性结合。免疫印迹和ELISA的稀释范围：1,000至80,000。用： 该抗体可用于检测血浆和脂蛋白中的载脂蛋白AII，免疫测定，免疫印迹，酶结合或生物素化。存储： -20°C长期保存，4°C短期保存。等分试样，以避免反复冻结和解冻。 *这些产品仅用于研究或制造用途，不能用于人体治疗或诊断应用。 重要性Apo AII占HDL的25％。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在，并通过二硫键连接。据报道，单链的分子量为8.7kDa（Brewer等，1972）。对小鼠的研究报道，apoAII可能具有促动脉粥样硬化作用（Warden等，1993）。然而，一项大型的欧洲前瞻性研究中的病例对照研究表明，血浆Apo AII浓度与冠心病事件密切相关（Birjmohun等，2007）。Birjmohun，RS，GM Dallinga-Thie，JA Kuivenhoven，ESg Stroes，JD Otvos，NJ Wareham，R.Luben，JJp Kastelein，K.-T. Khaw和SM Boekholdt。“载脂蛋白A-II与未来冠状动脉疾病的风险成反比。” 循环116（2007）：2029-035。Brewer，HB，SE Lux，R.Ronan和KM John。“人ApoLp-Gln-II（apoA-II），一种从高密度脂蛋白复合物中分离的载脂蛋白的氨基酸序列。” 美国国家科学院院刊69.5（1972）：1304-308。Warden，C.，C.Hedrick，J.Qiao，L.Castellani和A.Lusis。“过表达载脂蛋白A-II的转基因小鼠中的动脉粥样硬化。” 科学261（1993）：469-72。